Scivision Biotech (TPE:1786) Piotroski F-Score: 3 (As of Jul. 09, 2026) — 50% Below Median


TPE:1786 Scivision Biotech Inc TPE:1786
80 GF Score
Price NT$53.50
GF Value NT$115.23
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Scivision Biotech Piotroski F-Score?

Scivision Biotech TPE:1786 -0.56% 80 Piotroski F-Score is 3 as of Jul. 09, 2026, which is 50% below its 10-year median of 6.00. GuruFocus rates TPE:1786 with a GF Score™ of 80/100 and a GF Value™ of NT$115.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Scivision Biotech ranks worse than 76.89% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Scivision Biotech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Scivision Biotech's Piotroski F-Score or its related term are showing as below:

TPE:1786' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 3

During the past 13 years, the highest Piotroski F-Score of Scivision Biotech was 9. The lowest was 3. And the median was 6.

Scivision Biotech  (TPE:1786) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Scivision Biotech Piotroski F-Score Related Terms


Scivision Biotech Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Scivision Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scivision Biotech Piotroski F-Score Chart

Scivision Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 9.00 8.00 3.00

Scivision Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 6.00 6.00 4.00 3.00

TPE:1786 vs ISRG, BDX, MDLN: Piotroski F-Score Comparison

For the Medical Instruments & Supplies subindustry, Scivision Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scivision Biotech Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Scivision Biotech's Piotroski F-Score falls into.


TPE:1786
80GF Score
Scivision Biotech Inc TPE:1786
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 56.861 + -16.03 + 58.323 + 63.184 = NT$162.3 Mil.
Cash Flow from Operations was 115.223 + 6.377 + 15.412 + -13.024 = NT$124.0 Mil.
Revenue was 204.335 + 209.487 + 221.41 + 251.39 = NT$886.6 Mil.
Gross Profit was 142.17 + 152.787 + 154.084 + 189.352 = NT$638.4 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(2354.476 + 2443.72 + 2194.238 + 2609.867 + 2669.579) / 5 = NT$2454.376 Mil.
Total Assets at the begining of this year (Dec24) was NT$2,354.5 Mil.
Long-Term Debt & Capital Lease Obligation was NT$474.4 Mil.
Total Current Assets was NT$1,427.2 Mil.
Total Current Liabilities was NT$174.6 Mil.
Net Income was 51.704 + 67.81 + 57.174 + 65.566 = NT$242.3 Mil.

Revenue was 195.353 + 210.557 + 222.203 + 255.197 = NT$883.3 Mil.
Gross Profit was 152.266 + 153.555 + 160.352 + 189.511 = NT$655.7 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(2160.17 + 2251.719 + 2330.262 + 2146.264 + 2354.476) / 5 = NT$2248.5782 Mil.
Total Assets at the begining of last year (Dec23) was NT$2,160.2 Mil.
Long-Term Debt & Capital Lease Obligation was NT$84.7 Mil.
Total Current Assets was NT$1,166.4 Mil.
Total Current Liabilities was NT$337.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Scivision Biotech's current Net Income (TTM) was 162.3. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Scivision Biotech's current Cash Flow from Operations (TTM) was 124.0. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=162.338/2354.476
=0.06894867

ROA (Last Year)=Net Income/Total Assets (Dec23)
=242.254/2160.17
=0.1121458

Scivision Biotech's return on assets of this year was 0.06894867. Scivision Biotech's return on assets of last year was 0.1121458. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Scivision Biotech's current Net Income (TTM) was 162.3. Scivision Biotech's current Cash Flow from Operations (TTM) was 124.0. ==> 124.0 <= 162.3 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=474.446/2454.376
=0.19330616

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=84.723/2248.5782
=0.03767848

Scivision Biotech's gearing of this year was 0.19330616. Scivision Biotech's gearing of last year was 0.03767848. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=1427.168/174.648
=8.17168247

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=1166.418/337.07
=3.46046222

Scivision Biotech's current ratio of this year was 8.17168247. Scivision Biotech's current ratio of last year was 3.46046222. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Scivision Biotech's number of shares in issue this year was 91.155. Scivision Biotech's number of shares in issue last year was 78.373. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=638.393/886.622
=0.72002838

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=655.684/883.31
=0.74230338

Scivision Biotech's gross margin of this year was 0.72002838. Scivision Biotech's gross margin of last year was 0.74230338. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=886.622/2354.476
=0.37656871

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=883.31/2160.17
=0.40890763

Scivision Biotech's asset turnover of this year was 0.37656871. Scivision Biotech's asset turnover of last year was 0.40890763. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Scivision Biotech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Scivision Biotech (TPE:1786) has a Piotroski F-Score of 3 as of Jul. 09, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Scivision Biotech and its competitors. This is 50% below median its historical median of 6.00. Over the past decade, Scivision Biotech's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Scivision Biotech ranks #619 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 76.9%.
Is Scivision Biotech's Piotroski F-Score too high?
Scivision Biotech's current Piotroski F-Score of 3 is 50% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Scivision Biotech's value of 3 is 40% below this industry median. Based on the distribution chart, Scivision Biotech ranks #619 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #619 out of 805 companies for Piotroski F-Score. This places Scivision Biotech in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Scivision Biotech's value of 3 is 40% below this benchmark. Historically, Scivision Biotech's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Scivision Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Scivision Biotech and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current Piotroski F-Score is 3, which is 50% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current Piotroski F-Score is 3, which is 50% below median its 10-year median of 6.00 and 40% below the Medical Devices & Instruments industry median of 5.00. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Piotroski F-Score is 3 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scivision Biotech (TPE:1786) Overvalued in 2026?

Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued. The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23. GuruFocus considers Scivision Biotech to be Possible Value Trap.

Key valuation signals for TPE:1786:

  • Piotroski F-Score: 3 (50% below median its 10-year median of 6.00)
  • GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
  • GF Score™: 80/100 with 4 warning signs
  • Industry Position: 40% below the Medical Devices & Instruments median (#619 of 805)

No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scivision Biotech Business Description

Address No. 1, South 1st Road, Qianzhen District, Kaohsiung, TWN, 806
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
80GF Score

Get the complete analysis for TPE:1786

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$53.50
Price
NT$115.23
GF Value